Actively Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Led by Shanghai Huaota Biopharmaceutical Co., Ltd. · Updated on 2026-01-07
15
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
Sponsors
S
Shanghai Huaota Biopharmaceutical Co., Ltd.
Lead Sponsor
D
Dermatology Hospital affiliated to Shandong First Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
CONDITIONS
Official Title
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand the study and provide written informed consent
- Male or female, age 18 years or older
- Diagnosed with hidradenitis suppurativa for at least 6 months before screening
- Moderate to severe hidradenitis suppurativa with lesions in at least 2 distinct body areas
- At least one lesion at Hurley Stage II or III
- Total abscess and inflammatory nodule count of 3 or more
- If of childbearing potential, agree to use safe contraceptive methods throughout the study and for 6 months after
You will not qualify if you...
- Known allergy to HB0043 or its ingredients
- Having 20 or more draining fistulas at screening
- Other active autoimmune diseases besides hidradenitis suppurativa (e.g., psoriasis, rheumatoid arthritis)
- Any other active skin disease interfering with hidradenitis suppurativa assessment
- History of lymphoproliferative disorders or cancer within 5 years (except certain treated skin or breast cancers)
- History of recurrent or recent serious infections
- Active tuberculosis or being treated for latent tuberculosis
- Evidence of hepatitis B, hepatitis C, or HIV infection
- Pregnant or breastfeeding women
- Any condition that the investigator believes makes participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dermatology Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here